NL-OMON45830已完成不适用
A Phase 1 Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IV SYNT001 in Healthy Volunteers. - CS0307
Syntimmune0 个研究点目标入组 32 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Signed and dated informed consent form indicating the subject has read and understands the protocol and is willing to comply with all aspects of the study.
- •Male or female subject (non-childbearing potential) between the ages of 18 and 55 years, inclusive, at the time of screening.
- •Body mass index (BMI) range of 18.0 to 30.0 kg/m2 and body weight range of >50 kg to <120 kg.;For more inclusion criteria, please refer to protocol
排除标准
- •Contraindication and/or history of allergic or anaphylactic reactions to study drugs or its excipients.
- •Positive drug and alcohol test at Screening or on Day -1.
- •Any vaccination within 2 weeks of Screening.;For more exclusion criteria, please refer to protocol
研究者
相似试验
已完成
1 期
A Phase I, Dose-Escalating Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Intrathecal Infusion of KP-100IT through SM-1500 in Subjects with Amyotrophic Lateral Sclerosis (ALS)Amyotrophic lateral sclerosis (ALS)JPRN-UMIN000007062Kringle Pharma, Inc.15
已完成
不适用
A study in healthy males to assess the safety and tolerability of two different formulations of the study drug, (MSP-2017), administered intranasally.This study is for healthy volunteers. The intended use of the investigational product is to self-terminate acute episodes of paroxysmal supraventricular tachycardia (PSVT), a non-life threatening cardiac arrhythmia.Cardiovascular - Coronary heart diseaseACTRN12613000971730CPR Pharma Services48
已完成
不适用
A Phase 1, Dose Escalation Study to Evaluate the safety tolerability and pharmacokinetics of single oral doses of ELND007 in healthy elderly subjects.dementiaAlzheimerNL-OMON34459Elan Pharma42
进行中（未招募）
1 期
A study to investigate the safety, tolerability and efficacy of PCI/Gemcitabine treatment followed by combination chemotherapy in patients with cholangiocarcinomasInoperable advanced cholangiocarcinomasMedDRA version: 20.0Level: LLTClassification code 10008594Term: Cholangiocarcinoma non-resectableSystem Organ Class: 100000054936EUCTR2012-002888-10-GBPCI Biotech AS68
进行中（未招募）
1 期
A study to investigate the safety, tolerability and efficacy of PCI/Gemcitabine treatment followed by combination chemotherapy in patients with cholangiocarcinomasInoperable advanced cholangiocarcinomasMedDRA version: 20.0 Level: LLT Classification code 10008594 Term: Cholangiocarcinoma non-resectable System Organ Class: 100000004864EUCTR2012-002888-10-FRPCI Biotech AS61